Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, has announced that it has entered into a definitive agreement to be acquired by GTCR, a leading private equity firm with a long track record of investment expertise across healthcare and healthcare technology. Under the terms of the agreement, affiliates of GTCR will acquire all outstanding shares of Surmodics. Surmodics shareholders will receive US$43 per share in cash, for a total equity valuation of approximately US$627 million. The transaction is expected to close in the second half of calendar year 2024, subject to customary closing conditions.
Latham & Watkins LLP represented Oak Hill Advisors, L.P. and other financing sources in the transaction with a finance and hybrid capital team led by partners Stelios Saffos, Peter Sluka, Michael Saliba, and Zachary Judd, and counsel Marcela Ruenes, with associates Christian DeSimone, Ben Winnett, and Katherine Page. Advice was also provided on tax matters by partner Jiyeon Lee-Lim, with associate Nicholas Sun; and on uniform commercial code matters by partner Brian Rock.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
The advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
